Literature DB >> 22689800

Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.

Moritz Stuplich1, Dariusch R Hadizadeh, Klaus Kuchelmeister, Jasmin Scorzin, Christian Filss, Karl-Josef Langen, Niklas Schäfer, Frederic Mack, Heinrich Schüller, Matthias Simon, Martin Glas, Torsten Pietsch, Horst Urbach, Ulrich Herrlinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22689800     DOI： 10.1200/JCO.2011.40.9565

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  25 in total

1.  [Late and prolonged pseudoprogression in serial posttreatment MRI due to use of new chemotherapy concepts to treat malignant glioblastoma].

Authors:  O Ganslandt
Journal:  Strahlenther Onkol       Date:  2013-08       Impact factor: 3.621

2.  Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.

Authors:  Seymur Gahramanov; Csanad Varallyay; Rose Marie Tyson; Cynthia Lacy; Rongwei Fu; Joao Prola Netto; Morad Nasseri; Tricia White; Randy L Woltjer; Sakir Humayun Gultekin; Edward A Neuwelt
Journal:  CNS Oncol       Date:  2014-11

Review 3.  Conventional and advanced imaging throughout the cycle of care of gliomas.

Authors:  Gilles Reuter; Martin Moïse; Wolfgang Roll; Didier Martin; Arnaud Lombard; Félix Scholtes; Walter Stummer; Eric Suero Molina
Journal:  Neurosurg Rev       Date:  2021-01-07       Impact factor: 3.042

Review 4.  Multiparametric MRI as a potential surrogate endpoint for decision-making in early treatment response following concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Eur Radiol       Date:  2018-01-26       Impact factor: 5.315

Review 5.  From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

Authors:  Norbert Galldiks; Karl-Josef Langen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-06-30       Impact factor: 12.300

Review 6.  High-grade glioma management and response assessment-recent advances and current challenges.

Authors:  M N Khan; A M Sharma; M Pitz; S K Loewen; H Quon; A Poulin; M Essig
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

Review 7.  Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

Authors:  Benjamin M Ellingson; Caroline Chung; Whitney B Pope; Jerrold L Boxerman; Timothy J Kaufmann
Journal:  J Neurooncol       Date:  2017-04-05       Impact factor: 4.130

Review 8.  The evolving role for re-irradiation in the management of recurrent grade 4 glioma.

Authors:  Steven P Howard; Andra Krauze; Mike D Chan; Christina Tsien; Wolfgang A Tomé
Journal:  J Neurooncol       Date:  2017-04-06       Impact factor: 4.130

9.  Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Authors:  Norbert Galldiks; Veronika Dunkl; Gabriele Stoffels; Markus Hutterer; Marion Rapp; Michael Sabel; Guido Reifenberger; Sied Kebir; Franziska Dorn; Tobias Blau; Ulrich Herrlinger; Peter Hau; Maximilian I Ruge; Martin Kocher; Roland Goldbrunner; Gereon R Fink; Alexander Drzezga; Matthias Schmidt; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11-20       Impact factor: 9.236

10.  Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.

Authors:  Alexander Radbruch; Joachim Fladt; Philipp Kickingereder; Benedikt Wiestler; Martha Nowosielski; Philipp Bäumer; Heinz-Peter Schlemmer; Antje Wick; Sabine Heiland; Wolfgang Wick; Martin Bendszus
Journal:  Neuro Oncol       Date:  2014-07-18       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.